ITL Sells Custom Pack Business for $14.4 million

Custom Pack business sold to Merit Medical. ITL to keep growing BioMedical, creator of medical products for $3.3bn global blood culture testing sector; & MyHealthTest, creator & marketer of direct to consumer pathology testing for chronic diseases
By: ITL Health Group
 
MELBOURNE, Australia - Oct. 2, 2017 - PRLog -- ITL Sells Custom Pack Business for $14.4 million

Key Highlights


         -  Sale of Australian Custom Pack Business for $14.4m
         -  Strong Balance Sheet with net cash post sale of $10m approx.          -  ITL will continue with strategy to pursue high margin global blood market opportunities

ITL Health Group, an innovative global medical technology company, is pleased to announce the sale of its Australian Custom Pack business unit, part of the ITL Healthcare division, to Nasdaq-listed multi-national Merit Medical Systems, Inc. ("Merit") for $14.4m ("Sale"). The Sale was signed and completed on 2nd October 2017.

The Sale involves the transfer of all issued shares in ITL Healthcare Pty Ltd to a subsidiary of Merit and includes the Melbourne manufacturing facilities, clean rooms and steriliser, and ITL Healthcare's range of custom procedure packs, drapes and gowns.

ITL will retain a strong presence in Australia, including an extensive sales and distribution network across the country. ITL will retain ownership of business units that manufacture and sell the following products, that together contributed $8.9m in the last financial year:

         -  Invasive blood pressure monitoring kits (sold in 46 hospitals in Australia);
         -  Class 3 Intra Venous (IV) starter packs; and
         -  Numerous sponsored products.

The financial implications of the Sale include substantial strengthening of ITL's balance sheet; post settlement the Company will have net cash of $10m; profit on sale of approx. $10m* (against an asset book value of $4.2m); reduction of $12.3m in sales or 35% of Total Group sales of $34.8m in FY'17.

The Sale is consistent with ITL's strategy to pursue high margin opportunities in blood markets globally and target quick development of innovative patented products for these markets. This strategy has proven successful as shown in the considerable profit growth in the last financial year.

With a stronger balance sheet ITL will accelerate growth across the Group's remaining business units.

Bill Mobbs, ITL Executive Chairman commented; "The sale of the Custom Pack business sets a very solid foundation from which we can continue to drive growth in our higher margin and patented products across the global blood markets."


About ITL Health Group (ASX) http://ww.ITLHealthGroup.com (http://www.itlhealthgroup.com/)

ITL Health Group is an innovative global medical technology company that         creates and manufactures leading edge medical devices for the clinical, blood   banking, and laboratory markets. ITL is a growing provider of specialist ancillary  products for the blood culture testing market, estimated to be worth US$4.8bn by 2021.

ITL Health Group holds an IP portfolio of over 50 patents and sells into 55       countries, protecting healthcare workers in millions of procedures annually.

About Merit Medical Systems, Inc. (Nasdaq) http://ww.merit.com (http://www.merit.com/)

Founded in 1987, Merit is engaged in the development, manufacture and   distribution of proprietary disposable medical devices used in interventional,   diagnostic and therapeutic procedures, particularly in cardiology, radiology and   endoscopy.  Merit serves client hospitals worldwide with a domestic and   international sales force totaling approximately 290 individuals.  Merit employs   approximately 4,600 people worldwide with facilities in South Jordan, Utah;   Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland,   Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands;   Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil;   Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Singapore.

 * unaudited and based on pro forma June 2017 accounts

Contact
Ben Knowles - Walbrook Investor Relations
ben.knowles@walbrookir.com.au
+61 (0) 426 277 760
End
Source:ITL Health Group
Email:***@walbrookir.com.au Email Verified
Tags:Medical Devices, Medical Custom Pack, $4bn Blood Culture Test
Industry:Business
Location:Melbourne - Victoria - Australia
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share